Yes, Honeydew's board-certified dermatologists prescribe ICOTYDE entirely online. No in-person office visit is required. You complete a medical questionnaire covering your psoriasis history, previous treatments, and relevant health background, and a licensed dermatology provider reviews your case and determines whether ICOTYDE is the right fit.

If prescribed, your provider manages prior authorization with your insurance, coordinates with the pharmacy, and connects you with the ICOTYDE withMe patient support program. Medication is delivered to your door. Your Honeydew care team is available seven days a week for any questions during treatment, and your dermatologist will check in regularly to monitor your response, including assessing your clearance progress at the clinically significant week 16 milestone.

Yes. ICOTYDE is FDA-approved for adolescent patients ages 12 and older who weigh at least 88 pounds (40 kg). Both conditions, the age threshold and the weight threshold, must be met. The dosing schedule and administration instructions are the same as for adults: a 200 mg tablet taken once daily on an empty stomach with water upon waking, waiting at least 30 minutes before eating.

ICOTYDE's clinical development program included adolescent patients, and data through week 52 showed sustained clearance in this age group without new safety concerns beyond those identified in adults.

For patients under 18, a parent or guardian must be present for the initial Honeydew consultation. If your child's situation requires special accommodations, contact info@honeydewcare.com and the care team will assist.

Yes. Johnson & Johnson conducted a dedicated Phase 3 study (ICONIC-TOTAL) specifically evaluating ICOTYDE in patients with psoriasis in high-impact areas including the scalp, genitals, and palmoplantar regions (palms of the hands and soles of the feet). These are among the most difficult-to-treat and quality-of-life-impairing presentations of plaque psoriasis, and topical treatments alone are often inadequate.

Because ICOTYDE works systemically, traveling through the bloodstream to address inflammation throughout the body, it can reach and treat psoriasis in all these areas simultaneously, which topical treatments applied to individual locations cannot.

If your psoriasis primarily or significantly affects the scalp, genitals, or palms and soles, mention this during your Honeydew consultation. These high-impact locations are a specific clinical consideration in your provider's treatment decision.

Not technically, though it achieves biologic-level efficacy, which makes this a common point of confusion.

Traditional biologics (like Skyrizi, Tremfya, and Dupixent) are large protein molecules derived from biological sources and administered by injection because they can't survive the digestive process as a pill. ICOTYDE is classified as a targeted oral peptide: a small, engineered molecule specifically designed to survive digestion and reach the bloodstream intact. It blocks the same IL-23 receptor as injectable IL-23 biologics, but through a fundamentally different delivery mechanism.

In practical terms: ICOTYDE achieves comparable efficacy to injectable IL-23 biologics, but it's taken as a pill rather than an injection, which is why some clinicians describe it as "biologic-level" without it being a biologic in the traditional sense. The FDA approved it as a first-in-class treatment, an IL-23 receptor antagonist, rather than categorizing it alongside traditional biologics.

Yes, as a newly approved specialty medication, ICOTYDE will require prior authorization from most insurance plans before coverage kicks in. Many insurers will also require step therapy documentation, meaning evidence that other treatments (typically topical prescription medications or sometimes Otezla) were tried first before approving a newer oral systemic treatment.

Honeydew handles the entire prior authorization process on your behalf. Your provider prepares and submits the required documentation, follows up with your insurer, and coordinates with the pharmacy so treatment isn't delayed by paperwork. If your initial authorization is denied, we guide you through the appeals process and connect you with the ICOTYDE withMe patient support program in the interim.

Getting ICOTYDE prescribed online through Honeydew doesn't mean navigating insurance alone, we manage the access process from start to finish.

Otezla (apremilast) has been the most accessible oral psoriasis option for years, primarily because it tends to have easier insurance coverage than newer medications and doesn't require the same step therapy requirements as biologics. However, it's significantly less effective than ICOTYDE.

Otezla works by inhibiting PDE4, a broad anti-inflammatory mechanism. It achieves approximately 20% PASI 90 at week 16 which is meaningfully lower than ICOTYDE's approximately 55% PASI 90. For patients with moderate to severe psoriasis who want oral therapy and adequate clearance, ICOTYDE is a substantially stronger option.

The tradeoff is insurance access. Otezla has broader formulary coverage and is often easier to get approved without step therapy. ICOTYDE, as a newly approved medication, may face more prior authorization requirements, though Honeydew handles that process on your behalf.

If you're currently on Otezla and not achieving the skin clearance you want, ICOTYDE is worth discussing with your Honeydew provider as an upgrade. If getting the fastest possible insurance approval with the fewest hurdles is the priority, your provider will discuss which path makes most sense for your specific plan.

Skyrizi (risankizumab) and Tremfya (guselkumab) are injectable IL-23 inhibitors and currently the most effective psoriasis treatments available, achieving approximately 70-74% PASI 90 at week 16 in pivotal trials. ICOTYDE targets the same IL-23 pathway and achieves comparable clearance rates (approximately 55-70% PASI 90 at week 16 across ICONIC trials) and is delivered as a once-daily pill rather than an injection.

The key practical differences come down to administration and dosing frequency. Skyrizi requires just 4-5 injections per year after initial doses. Tremfya requires injections every 8 weeks. ICOTYDE requires a pill every single day. A higher daily commitment than either injectable, but without any injections.

For patients who specifically want to avoid injections and are comfortable with a daily pill routine, ICOTYDE delivers results that are in the same clinical range as the best injectable IL-23 inhibitors. For patients who are comfortable with injections and prefer less frequent dosing, Skyrizi or Tremfya may be the better practical choice. Your Honeydew dermatologist will consider your treatment history, lifestyle, and insurance coverage when recommending between these options — and Honeydew prescribes all three.

Sotyktu (deucravacitinib) was the leading oral psoriasis treatment before ICOTYDE's approval in March 2026. Both are once-daily pills for moderate to severe plaque psoriasis, but they work through different mechanisms and achieve meaningfully different results.

Sotyktu is a TYK2 inhibitor: it works by blocking an intracellular enzyme involved in inflammatory signaling across multiple pathways. ICOTYDE is an IL-23 receptor antagonist: it works by directly blocking the IL-23 receptor, the same target as the most effective injectable biologics.

The efficacy difference is significant. In head-to-head Phase 3 trials, ICOTYDE outperformed Sotyktu on both primary endpoints: IGA 0/1 (clear or almost clear skin) and PASI 90 (90% reduction in disease severity). ICOTYDE achieves approximately 70% PASI 90 at week 16; Sotyktu achieves approximately 40% PASI 90. ICOTYDE is currently the most effective oral psoriasis treatment available.

If you're currently on Sotyktu and not achieving adequate skin clearance, ICOTYDE may be worth discussing with your Honeydew provider as a next step.

Yes, icotrokinra is the generic (scientific) name for ICOTYDE. You may see "icotrokinra" on your prescription label, insurance paperwork, or pharmacy receipt. It is the same medication. ICOTYDE is the brand name manufactured by Johnson & Johnson.

Icotrokinra is classified as a targeted oral peptide: a small, engineered molecule specifically designed to survive digestion, reach the bloodstream intact, and precisely block the IL-23 receptor. This mechanism is what distinguishes it from other oral psoriasis medications, which work through different and generally less targeted pathways.

Johnson & Johnson has not published a public list price for ICOTYDE as of mid-2026. What J&J has launched is the ICOTYDE withMe program, a patient support program that provides cost support options, a dedicated nurse guide, and educational resources regardless of your insurance type. Whether you have commercial insurance, government coverage, or no insurance, the withMe program is the starting point for understanding your access options.

Honeydew handles insurance verification and prior authorization on your behalf before you start treatment, so coverage is confirmed upfront. If your insurance requires step therapy or documentation before approving ICOTYDE, your provider prepares and submits that paperwork so you don't manage it alone.

For the most current pricing and savings card details, your Honeydew care team can direct you to the withMe program and help you navigate what's available for your specific insurance situation.

Yes, and this is what makes ICOTYDE genuinely different from the most effective psoriasis treatments available before it. Until March 2026, patients who needed biologic-level results for moderate to severe plaque psoriasis had to choose between injectable medications like Skyrizi and Tremfya. ICOTYDE is the first oral treatment to deliver comparable clearance rates to those injectable IL-23 biologics.

Johnson & Johnson estimates that approximately 75% of patients with moderate to severe psoriasis haven't advanced from topical treatments to systemic therapy and needle fear is one of the most commonly cited reasons. ICOTYDE is specifically designed for this audience: patients who need more than topicals can offer but have been reluctant to start injections.

If you're currently managing moderate to severe psoriasis with topicals that aren't providing adequate control, or if you've been told you need a biologic but don't want injections, ICOTYDE may be worth discussing with a Honeydew dermatologist.

If you or your child is under the age of 18, a parent or guardian should be part of the initial consultation. In circumstances where this is not possible, please contact info@honeydewcare.com and we will assist you with alternate ways to establish parental consent.

We will run the prescriptions through your insurance and help you find the lowest costs out there. The membership fee and any products are also eligible for HSA or FSA reimbursement.

We offer comprehensive support for our patients, including access to experienced providers, assistance with lab orders and the iPledge program (when needed), unlimited support, and progress tracking.